Kecskemét

• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-experienced Participants with Active Psoriatic Arthritis Recruiting
  2024-517284-23-00 5 2025-04-23 Active Psoriatic Arthritis
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad … Recruiting
  2023-505077-32-00 5 2025-01-28 Locally-advanced or metastatic non-squamous non-small cell lung cancer
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 4 2025-01-27 Crohn's disease
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting
  2023-510128-66-00 5 2024-09-02 Participants with treatment-naïve metastatic squamous Non-small Cell L
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• A Study Evaluating the Overall Survival of Patients with Extensive Stage Small Cell Lung Cancer Receiving Trilaciclib or Placebo prior to To … Recruiting
  2022-502357-34-00 5 2023-09-27 Extensive Stage Small Cell Lung Cancer
• Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting
  2023-508852-21-00 4 2022-06-10 Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Study to assess whether Verekitug can improve the control of Chronic Obstructive Pulmonary Disease (COPD) Ended recruitment
  2025-520488-42-00 4 2025-09-17 Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended recruitment
  2024-510719-31-00 5 2025-01-24 Moderate to Severe Vasomotor Symptoms (VMS)

Showing 49–72 of 137 trials